SafeBeat Rx Analysis: $130K Raised
What is SafeBeat Rx?
SafeBeat Rx develops AI-powered cardiac monitoring solutions for remote patient care, enhancing diagnostics and treatment recommendations via mobile technology.
Employees
9
Founded
2020
Revenue
$5M-$10M
Business Model
Revenue generated through service subscriptions, software licensing, and healthcare partnerships.
Product Features & Capabilities
- Remote patient monitoring (RPM), mobile ECG, mobile cardiac telemetry, implantable cardiac monitor, software-enabled therapeutic monitoring, artificial intelligence algorithms for ECG interpretation, treatment management recommendations.
How much SafeBeat Rx raised
Y Combinator - $130,000
August 2021Lead Investor: Y Combinator
Who are the founders of SafeBeat Rx
RN
Rachita Navara
Co-founder and CEO
KP
Kunj Patel
Co-founder, President, CTO
Competitors Overview
SafeBeat Rx operates in the remote cardiac monitoring market, utilizing AI technology for enhanced patient care. Its main competitors include:
- Eko: Specializes in digital stethoscopes and ECG devices, offering a platform for remote monitoring of heart conditions. Eko's advantage lies in its
Market Focus
SafeBeat Rx primarily focuses on the healthcare industry, specifically in the field of cardiac care through the use of artificial intelligence for remote patient monitoring and therapeutic monitoring.
Investors
- HeartX Accelerator
- Defense TechConnect
- MedTech Innovator
- Y Combinator
- LG Nova
- Zillionize
See something that needs updating? Suggest edits to this profile.